GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxil Bio Ltd (OTCPK:VXLLF) » Definitions » ROCE %

VXLLF (Vaxil Bio) ROCE % : -24.16% (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Vaxil Bio ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vaxil Bio's annualized ROCE % for the quarter that ended in Jun. 2024 was -24.16%.

Vaxil Bio ROCE % Historical Data

The historical data trend for Vaxil Bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxil Bio ROCE % Chart

Vaxil Bio Annual Data
Trend May14 May15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -1,084.54 -78.73 -39.74 -25.73

Vaxil Bio Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.62 -14.72 11.69 -26.85 -24.16

Vaxil Bio ROCE % Calculation

Vaxil Bio's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-0.193/( ( (1.134 - 0.298) + (0.727 - 0.063) )/ 2 )
=-0.193/( (0.836+0.664)/ 2 )
=-0.193/0.75
=-25.73 %

Vaxil Bio's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2024 )  (Q: Mar. 2024 )(Q: Jun. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2024 )  (Q: Mar. 2024 )(Q: Jun. 2024 )
=-0.144/( ( (0.689 - 0.072) + (0.63 - 0.055) )/ 2 )
=-0.144/( ( 0.617 + 0.575 )/ 2 )
=-0.144/0.596
=-24.16 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxil Bio  (OTCPK:VXLLF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vaxil Bio ROCE % Related Terms

Thank you for viewing the detailed overview of Vaxil Bio's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxil Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxil Bio Ltd (OTCPK:VXLLF) » Definitions » ROCE %
Comparable Companies
XCNQ:NIRV TSXV:WAVE TSXV:SVS XCNQ:CMND TSX:IPCI TSXV:MRVL TSXV:PSYB XCNQ:CURE XCNQ:AGN XCNQ:MOOD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
3400 One First Canadian Place, Toronto, ON, CAN, M5X 1A4
Website
https://www.vaxil-bio.com
Vaxil Bio Ltd is an Israeli immunotherapy biotech company focused on a novel drug discovery and development platform based on Signal Peptides which the company deploys to fight infectious diseases and cancer.